Routine Genomic Testing is Feasible, But Only a Subset of Patients Benefit

Summary includes updated data not in the abstract
For immediate release
June 3, 2017
Contact
Kelly Baldwin
571-483-1365
Kelly.Baldwin@asco.org

ASCO Perspective

“This study gives more validation for the use of genomics in clinical practice and shows it could very well guide treatment choices for patients with advanced cancer,” said Sumanta Kumar Pal, MD, ASCO Expert. “These data are particularly interesting in the face of recent approvals for immunotherapy for patients who have evidence of genomic instability.”

CHICAGO – Genomic testing of tumor samples can enable personalized treatment selection, where targeted treatments are matched to genetic changes in the tumor. Although a growing number of patients with advanced cancers receive some genomic testing, comprehensive genomic testing is not yet routine care.

A study in France of 1,944 patients with advanced cancer suggests that widespread, routine genomic testing is feasible, although it offers clinical benefit to only a subset of patients at this time. According to the authors, this is the largest study of its kind.

The study will be featured in a press briefing today and presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

The researchers found least one “actionable” alteration in 52% of the tumor samples tested (“actionable” alterations are genetic changes that theoretically can be matched to targeted therapies). A molecular tumor board recommended targeted treatments to 676 patients, and 143 of them received the recommended treatment. The five-year survival rate was higher among patients who received the recommended treatment than among those who did not (34.8% vs. 28.1%).

“This study confirms that comprehensive genomic profiling can be performed in routine practice to
select patients for targeted cancer therapies,” said lead study author Olivier Tredan, MD, PhD, chair of the Department of Medical Oncology at the Centre Léon Bérard in Lyon, France. “The technology is widely available and requires only a small amount of DNA. Theoretically, we could do this testing for every patient in France.”

About the Study
ProfiLER is an ongoing clinical trial that uses genomic profiling of tumors to guide treatment decisions for patients with advanced cancer. DNA from tumor samples is analyzed by next-generation sequencing of 69 cancer-related genes and whole-genome-comparative genomic hybridization. Both technologies are widely available in France and elsewhere in the world, according to the authors.

A multidisciplinary board of experts (the molecular tumor board) meets weekly to review genomic testing results and, if actionable mutations are found, provides recommendations for molecularly targeted therapies.

“We recommended molecularly targeted therapies to patients who had mutations in pathways that could be targeted with either commercially available drugs or those tested in early clinical trials,” said Dr. Tredan.

Key Findings
To date, 2,676 patients have enrolled in the study, and 1,944 tumors were analyzed, including colorectal, gynecologic, breast, brain, and head and neck cancer, as well as sarcoma. Actionable mutations were found in 1,004 (52%) of tumor samples; 609 patients had only one actionable mutation, and 394 had two or more (up to six). The most common actionable pathway was the PI3K/mTOR pathway.

The molecular tumor board recommended molecularly targeted treatments to 676 patients (35% of 1,944 tested) based on availability of drugs hitting either the target protein or the pathway activated by the target. Of those, 143 received the recommended treatment, most through enrollment in a clinical trial. The other 533 patients were not able to receive the recommended treatment because of poor health/rapid progression of the cancer, not meeting eligibility criteria for a clinical trial, or difficulty obtaining off-label commercial medicines.

Researchers compared overall survival rates for the 143 patients who received targeted therapies based on genomic testing and 502 patients who did not. At three years, 53.7% of patients who received the recommended targeted therapy were alive, compared to 46.1% of patients who did not. The five-year survival rate was also higher for patients who received targeted therapy (34.8% vs. 28.1%).

Next Steps
The researchers are planning a new, randomized clinical trial, ProfiLER 02, which will compare the 70-gene test used in the current study to a commercial, 315-gene test. That trial should reveal whether screening a larger number of genes leads to more recommendations for targeted therapy.

This study was funded by LYRIC and BPI France Financement abounded by European Community.

View the full abstract.

For your readers:

- Understanding Targeted Therapy
- After the Biopsy: Making the Diagnosis

View the disclosures for the 2017 ASCO Annual Meeting News Planning Team.

ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.

###

About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.